Showing 2811-2820 of 4063 results for "".
- Amarantus Announces Issuance of US Patent Covering MANF Treatment of Wolfram’s Syndrome, Retinitis Pigmentosa, and Glaucomahttps://modernod.com/news/amarantus-announces-issuance-of-us-patent-covering-manf-treatment-of-wolframs-syndrome-retinitis-pigmentosa-and-glaucoma/2476653/Amarantus Bioscience Holdings announced that subsidiary MANF Therapeutics was issued US Patent No. 10,195,251 entitled “Methods of Treatment for Retinal Diseases Using MANF and CDNF” that covers the use of mesencephalic astrocyte-derived neurotrophic factor (MANF) or cerebral dopamine
- Immunocore to Present New Tebentafusp (IMCgp100) Data in Advanced Melanoma at Upcoming 2019 ASCO Annual Meetinghttps://modernod.com/news/immunocore-to-present-new-tebentafusp-imcgp100-data-in-advanced-melanoma-at-upcoming-2019-asco-annual-meeting/2476605/Immunocore Limited, a T cell receptor (TCR) biotechnology company, will present new mechanism of action data in advanced uveal and cutaneous melanoma from the tebentafusp clinical research program at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 3, 2019. Teben
- Alcon Reports First Quarter 2019 Trading Updatehttps://modernod.com/news/alcon-reports-first-quarter-2019-trading-update/2476592/Alcon reported selected financial results for the first quarter ending March 31, 2019, and provided financial guidance for the current fiscal year. For the first quarter of 2019, worldwide net sales were $1.8 billion, flat on a reported basis and an increase of 4 percent on a constant currency ba
- Atia Vision Closes $20M In Series D Financing to Fund Accommodating IOLhttps://modernod.com/news/atia-vision-closes-20m-in-series-d-financing-to-fund-accommodating-iol/2476533/Atia Vision, a Shifamed portfolio company developing a modular presbyopia-correcting accommodating IOL, announced initial closing of its committed $20 million Series D preferred stock
- Optos Wins 2019 Queen’s Award for Enterprise Innovationhttps://modernod.com/news/optos-wins-2019-queens-award-for-enterprise-innovation/2476489/UK-based Optos has been recognized for its innovation with a 2019 Queen’s Award for Enterprise. Optos, which has sold more than 16,000 of its ultra-widefield imaging devices to eyecare professionals across the world, won the coveted accolade for the design of its
- Academy 2019 Orlando and 3rd World Congress of Optometry Education Program Announcedhttps://modernod.com/news/academy-2019-orlando-and-3rd-world-congress-of-optometry-education-program-announced/2476458/The World Council of Optometry and the American Academy of Optometry have partnered to present an impressive education program taking place at Academy 2019 Orlando and the 3rd World Congress of Optometry, October 23 to 27, 2019. This joint meeting will bring global optometry together t
- Aldeyra Therapeutics to Present Phase 2b Dry Eye Disease Results at ARVOhttps://modernod.com/news/aldeyra-therapeutics-to-present-phase-2b-dry-eye-disease-results-at-arvo/2476456/Aldeyra Therapeutics announced that John Sheppard, MD, Professor of Ophthalmology at Eastern Virginia Medical School, will present results of the phase 2b clinical trial of topical reproxalap in dry eye disea
- AOA Announces 2019 National Optometry Hall of Fame Inducteeshttps://modernod.com/news/aoa-announces-2019-national-optometry-hall-of-fame-inductees/2476443/The American Optometric Association has announced the four ODs who will be inducted into the National Optometry Hall of Fame in 2019. This year’s inductees are: Murray Fingeret, OD; Donald Jarnagin, OD; Michael Mittelman, OD; and Glen Steele, OD.
- IStent Inject Device Lowers IOP After Cataract Surgery in Glaucoma Patientshttps://modernod.com/news/istent-inject-device-lowers-iop-after-cataract-surgery-in-glaucoma-patients/2476438/In patients with mild to moderate glaucoma and cataract, the second-generation iStent inject system, with two redesigned stents, reduces IOP more than cataract surgery alone, according to results of a new pivotal trial, as reported by Reut
- Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopiahttps://modernod.com/news/orasis-announces-initiation-of-phase-2b-clinical-study-of-csf-1-for-the-treatment-of-presbyopia/2476421/Orasis Pharmaceuticals announced the initiation of a phase 2b clinical study in the United States evaluating CSF-1 for the treatment of presbyopia. The phase 2b study is a multicenter, double-masked trial in the United States enrolling 150 participants with presbyopia to evaluate the efficacy and